🧬 Tirzepatide: The 2025 Breakthroughs You Should Know. New May 2025 Study.
By Paul The Bio-Hacker
Let’s cut the fat—literally and figuratively. If you’ve been watching the peptide world like a hawk with a glucose monitor, you already know tirzepatide isn’t just riding the GLP-1 wave—it’s steering the whole damn ship. But the last six months have been something else.
From crushing semaglutide in clinical trials to showing it might just be the Swiss Army knife of metabolic optimization, here’s what every researcher, self-experimenter, and metabolic rebel should know.
🥇 Tirzepatide vs Semaglutide: The Fat-Loss Heavyweight Battle
In May 2025, the New England Journal of Medicine published the results of SURMOUNT-5—a 72-week trial pitting tirzepatide (Zepbound) against semaglutide (Wegovy) in 751 adults with obesity.
Final score:
-
🧬 Tirzepatide: 20.2% weight loss
-
🥬 Semaglutide: 13.7% weight loss
-
🎯 Bonus: More waist-shrinking action with tirzepatide
Why such a big difference? Tirzepatide is a dual agonist, tickling both the GLP-1 and GIP receptors. It’s like semaglutide... with a booster pack. I say this all the time and I don't make any money off it yet 😉 but the best prices & quality Tirz 30mg are at Apex Peptides & Research USA.
Source: NEJM Study – SURMOUNT-5
📆 Long-Term Win: 3 Years of Fat Loss (Without Rebounding Like a Trampoline)
At the European Congress on Obesity (ECO) 2025, data from the extended SURMOUNT-1 trial showed:
-
Average weight loss of 23.1%
-
Minimal weight regain: only 3.7% after 3 years
-
70% of users regained less than 5% of their lost weight
This isn’t some crash diet nonsense. Tirzepatide helps you stay optimized—like a good supplement stack that actually works, but for your entire metabolism.
Source: EASO Highlights – ECO 2025
🔥 Appetite: Crushed. Fat Oxidation: Boosted.
A Pennington Biomedical study, published in Cell Metabolism, unpacked the how behind tirzepatide’s magic:
-
Suppresses appetite like a champ
-
Increases fat oxidation
-
Does not prevent the classic metabolism slow-down (sorry, nothing’s perfect)
Still, combine it with mitochondrial boosters like MOTS-c, and you might just dodge the dreaded metabolic crawl.
Source: Pennington Study
💥 Retatrutide: The Triple Threat Enhancer
In one of the most promising studies of 2025, researchers explored the effects of Retatrutide, a triple agonist (GLP-1, GIP, and glucagon receptors), as an advanced fat loss agent.
💣 What they found:
-
When combined with or benchmarked against tirzepatide, Retatrutide produced an additional 9% weight loss
-
That’s a potential 29%+ total reduction in body weight
-
Side effect profile was manageable and similar to other incretin-based therapies
This new class of multi-agonists is redefining what’s possible in metabolic medicine. In other words, tirzepatide may not even be the final boss—we may be entering the Retatrutide era.
🌙 Tirzepatide: Now Approved for More Than Weight Loss
The past six months have shown tirzepatide isn’t just a fat shredder—it’s a metabolic Swiss army knife:
-
💤 Sleep Apnea: FDA approved for moderate-to-severe cases tied to obesity
-
❤️ Heart Failure: 38% risk reduction in the SUMMIT study
-
🍖 Liver Health: In SYNERGY-NASH, tirzepatide helped resolve MASH and even improved fibrosis scores
Honestly, if tirzepatide were a supplement, it would have about 19 bullet points on the bottle. Thankfully, the science backs every one of them.
Source: Medpace Recap
💡 Final Thoughts from Paul The Bio-Hacker
Tirzepatide is no longer “that new peptide on the block.” It's a well-documented powerhouse with results that would make your endocrinologist do a double take.
Whether you’re stacking it with Cagrilintide, pairing it with GHK-Cu, or planning for Retatrutide’s debut, one thing is clear:
The future of fat loss isn’t coming. It’s already here.
Stay sharp, stay lean, and biohack smart.
— Paul The Bio-Hacker